These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28824834)

  • 21. Current needs in pediatric pharmacoepidemiology.
    Lasky T; Artaman A; Czaja AS; Maruti SS; Osokogu OU; Verhamme KM; Sobel RE
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):738-42. PubMed ID: 26910571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. More realistic power estimation for new user, active comparator studies: an empirical example.
    Gokhale M; Buse JB; Pate V; Marquis MA; Stürmer T
    Pharmacoepidemiol Drug Saf; 2016 Apr; 25(4):462-6. PubMed ID: 26360635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The importance and implications of comparator selection in pharmacoepidemiologic research.
    D'Arcy M; Stürmer T; Lund JL
    Curr Epidemiol Rep; 2018 Sep; 5(3):272-283. PubMed ID: 30666285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacoepidemiologic Methods for Studying the Health Effects of Drug-Drug Interactions.
    Hennessy S; Leonard CE; Gagne JJ; Flory JH; Han X; Brensinger CM; Bilker WB
    Clin Pharmacol Ther; 2016 Jan; 99(1):92-100. PubMed ID: 26479278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interpretation of associations in pharmacoepidemiology.
    Kaufman DW
    Semin Hematol; 2008 Jul; 45(3):181-8. PubMed ID: 18582625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bias in pharmacoepidemiologic studies using secondary health care databases: a scoping review.
    Prada-Ramallal G; Takkouche B; Figueiras A
    BMC Med Res Methodol; 2019 Mar; 19(1):53. PubMed ID: 30871502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. When do we need competing risks methods for survival analysis in nephrology?
    Noordzij M; Leffondré K; van Stralen KJ; Zoccali C; Dekker FW; Jager KJ
    Nephrol Dial Transplant; 2013 Nov; 28(11):2670-7. PubMed ID: 23975843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacoepidemiology I: a review of pharmacoepidemiologic study designs.
    Etminan M; Samii A
    Pharmacotherapy; 2004 Aug; 24(8):964-9. PubMed ID: 15338844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Competing risks in clinical research].
    van Kruijsdijk RC; Eijkemans MJ; Visseren FL
    Ned Tijdschr Geneeskd; 2012; 156(46):A5176. PubMed ID: 23151330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival analysis in total joint replacement: an alternative method of accounting for the presence of competing risk.
    Fennema P; Lubsen J
    J Bone Joint Surg Br; 2010 May; 92(5):701-6. PubMed ID: 20436009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Understanding and Avoiding Immortal-Time Bias in Gastrointestinal Observational Research.
    Targownik LE; Suissa S
    Am J Gastroenterol; 2015 Dec; 110(12):1647-50. PubMed ID: 26323186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimation of the marginal survival time in the presence of dependent competing risks using inverse probability of censoring weighted (IPCW) methods.
    Matsuyama Y; Yamaguchi T
    Pharm Stat; 2008; 7(3):202-14. PubMed ID: 17554753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Case-crossover study design in pharmacoepidemiology: systematic review and recommendations.
    Consiglio GP; Burden AM; Maclure M; McCarthy L; Cadarette SM
    Pharmacoepidemiol Drug Saf; 2013 Nov; 22(11):1146-53. PubMed ID: 24030723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Bias and confounding: pharmacoepidemiological study using administrative database].
    Nojiri S
    Yakugaku Zasshi; 2015; 135(6):793-808. PubMed ID: 26028416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimating sample size in the presence of competing risks - Cause-specific hazard or cumulative incidence approach?
    Tai BC; Chen ZJ; Machin D
    Stat Methods Med Res; 2018 Jan; 27(1):114-125. PubMed ID: 26711503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The importance of censoring in competing risks analysis of the subdistribution hazard.
    Donoghoe MW; Gebski V
    BMC Med Res Methodol; 2017 Apr; 17(1):52. PubMed ID: 28376736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A missing data approach to semi-competing risks problems.
    Dignam JJ; Wieand K; Rathouz PJ
    Stat Med; 2007 Feb; 26(4):837-56. PubMed ID: 16755544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacoepidemiology in the postmarketing assessment of the safety and efficacy of drugs in older adults.
    Hilmer SN; Gnjidic D; Abernethy DR
    J Gerontol A Biol Sci Med Sci; 2012 Feb; 67(2):181-8. PubMed ID: 21653991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methodology for analyzing episodic events.
    Eisen EA
    Scand J Work Environ Health; 1999; 25 Suppl 4():36-42. PubMed ID: 10628439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reproductive health indicators and fetal medicine - many things will change.
    Olsen J; Pedersen LH
    Scand J Work Environ Health; 2016 Jun; 42(6):561-562. PubMed ID: 27685865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.